2021
DOI: 10.1101/2021.08.05.455324
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Conjugates for use in peptide therapeutics: a systematic review and meta-analysis

Abstract: While peptides can be excellent therapeutics for several conditions, their limited in vivo half-lives have been a major bottleneck in the development of therapeutic peptides. Conjugating the peptide to an inert chemical moiety is a strategy that has repeatedly proven to be successful in extending the half-life of some therapeutics. This systematic review and meta-analysis was conducted to examine the available literature and assess it in an unbiased manner to determine which conjugates, both biological and syn… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 46 publications
0
1
0
Order By: Relevance
“…Conjugation to the Fc fragments of antibodies has been used as a half-life extension strategy in peptide drug design. These peptides are known as Antibody-Drug Conjugates (ADCs) (6). The ADCs are taken into all consideration of peptide drugs in this paper.…”
mentioning
confidence: 99%
“…Conjugation to the Fc fragments of antibodies has been used as a half-life extension strategy in peptide drug design. These peptides are known as Antibody-Drug Conjugates (ADCs) (6). The ADCs are taken into all consideration of peptide drugs in this paper.…”
mentioning
confidence: 99%